The FDA’s Commissioner’s National Priority Voucher program, unveiled in June 2025, is “shrouded in secrecy,” Democratic representative Jake Auchincloss said last month, as regulatory and biopharma ...

Chugai Pharmaceutical Co. fell 7.3%, the largest intraday decline since August 2025, after the company said it had ended the ...

The blockbuster weight loss drug sold as Ozempic and Wegovy will soon go generic in countries that are home to 40% of the ...

Structure Therapeutics advances oral therapies for diabetes, obesity, and pulmonary disease through its clinical-stage drug pipeline.

An all-of-the-above strategy is needed to head off Australia's worsening obesity problem, bipartisan research finds.

Researchers at the University of Bristol have identified a specific biological mechanism by which GLP-1 drugs, the same class ...

Researchers at the University of Colorado Boulder have identified a molecule in Burmese python blood that suppresses appetite ...

India’s ₹1,446 crore glucagon-like peptide (GLP-1) agonist market is set to get a shot in the arm, with at least 16 generic ...

The global weight-loss treatment market has not had it so good in ages. From a ‘class’ drug priced at a prohibitive ₹10,000 a month and above, the jab’s cost dr ...

Wall Street and healthcare stocks sank as Eli Lilly was downgraded, Novo’s Wegovy HD won FDA approval, and drug supply risks rose.

GLP-1 medications like semaglutide (Ozempic) may offer unexpected mental health benefits alongside weight loss. A large study found major drops in depression, anxiety, and psychiatric-related hospital ...

In that vein, Bitcoin (CRYPTO: BTC) and Viking Therapeutics (NASDAQ: VKTX) sit at opposite ends of the asset spectrum, with ...